A research-based solution exploring how combining phosphite treatments with beneficial soil biota can synergistically reduce root rot disease (Phytophthora cinnamomi) mortality in Rhododendron and over 5000 plant species. This approach aims to decrease chemical inputs while enhancing plant disease resistance through improved nutrient uptake and immune response.
Root rot disease caused by Phytophthora cinnamomi damages over 5000 plant species globally, resulting in billions of dollars in annual losses across vegetable crops and horticulture. While phosphite is an established treatment for symptomatic plants, its interaction with soil biota has not previously been explored. This research investigates whether phosphite and beneficial soil microorganisms act synergistically to reduce disease-induced plant mortality, potentially enabling lower chemical application rates while maintaining or improving protection.
The proposed solution addresses a critical gap in integrated disease management by combining a proven chemical treatment with the natural protective functions of soil biota, including mycorrhizal fungi that enhance plant nutrient acquisition. This synergy could significantly reduce the volume of phosphite required for effective disease control, lowering costs and environmental impact for growers.
Core approach:
Experimental design:
This research is at an early validation stage (TRL 2-3). The hypothesis is supported by existing literature showing soil biota's protective function and preliminary experiments suggesting phosphite efficacy at low prophylactic levels. However, the critical interaction between soil biota and phosphite has not yet been empirically tested. The planned factorial experiment will provide the first systematic validation of this synergistic approach. Findings will establish proof-of-concept for an integrated disease management strategy applicable to the broader horticulture industry.
Case Western Reserve University is a comprehensive private research university anchored in Cleveland’s University Circle with a high‑intensity research enterprise. Its campus is co‑located with major hospital systems, giving industry partners access to clinical collaborators, regulatory know‑how, and real‑world validation environments. A large open‑access makerspace, shared core facilities, and an engineering co‑op program connect companies to rapid prototyping, testing, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office, working with corporate engagement and entrepreneurship programs, supports IP strategy, licensing, sponsored research, and startup formation.